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Interferon-gamma release assays are being increasingly used
worldwide for the diagnosis of latent tuberculosis (TB) in
patients of all ages, including children [1]. A PubMed search
with ‘interferon-gamma release assays’ as keyword revealed
a total of 1077 references, up to 100 of which had been
released in 2012, including several reviews. In national and
international guidelines such as CDC [2], ECDC [3], Cana-
dian [4], French [5] and UK [6] guidelines, interferon-gamma
release assays are used either in place of or in addition to
the tuberculin skin test for latent TB diagnosis, indicating the
lack of clear evidence regarding the use of interferon-gamma
release assays. There are two major interferon-gamma
release assays available: the quantiFERON-TB Gold in-Tube
assay, which is an ELISA from Cellestis (Chadstone, Australia),
and the T-SPOT.TB assay, which is an enzyme-linked immuno-
spot assay from Oxford Immunotec (Abingdon, UK). The devel-
opment of these tests opens to a fruitful market. ‘We now have
market penetration about 2 million tests per year—about 1
QFT test every 15 seconds’ said Ron Pitcher in the Cellestis
2010 Annual Report (available at: http://www.cellestis.com/
IRM/Company/ShowPage.aspx?CPID=
1807&EID=45312332). Similarly, in a 2012 Oxford Immunotec
press release (available at: http://www.oxfordimmuno
tec.com/Default.aspx?DN=76c77774-47ed-4b1a-876c-4325fa-
ebe75f), it was said that the ‘T-SPOT.TB test is approved for
sale in Europe, USA, Canada, and over 40 other coun-
tries … addressing a market exceeding 1 billion dollars’.
Mycobacterium tuberculosis primary infection is mainly
asymptomatic. It has been well documented that preventive
treatment of asymptomatic primary infection reduces the
risk of active TB [7,8]. If untreated, latent TB may reactivate,
mostly under immunocompromised conditions. According to
Baye’s theorem, the positive predictive value of interferon-
gamma release assays increases when the disease prevalence
increases [9]. Consequently, in non-endemic countries, to be
signiﬁcant the test should be performed in targeted popula-
tions such as TB-exposed individuals. This is well illustrated
in these two following studies. In Portugal, 2889 healthcare
workers were systematically tested with both the tuberculin
skin test and interferon-gamma release assays; 850 tested
positive with both tests, none were preventively treated,
eight were ﬁnally diagnosed with active TB, and four others
progressed to TB within 4–24 months [10]. In this study, the
preventive treatment would have be given to 842 persons to
prevent four active TB cases. This demonstrates the poor
cost-effectiveness of systematic screening. However, in
TB-exposed individuals, 2.3–14.6% of those with positive
tuberculin skin test results or interferon-gamma release assay
results, respectively, will develop active TB [11].
The main purpose of interferon-gamma release assays is
to allow the treatment of patients with latent TB at risk of
developing active TB, such as TB-exposed individuals or
immunocompromised patients. Only patients who would
beneﬁt from preventive treatment should be tested. The
decision to test presupposes a decision to treat if the test
result is positive.
Misuse: There is no indication for the use of these tests in
systematic screening. Because the available evidence is cur-
rently inconsistent, interferon-gamma release assays should
not be used to monitor response to TB therapy. Neither
tuberculin skin tests nor interferon-gamma release assays can
distinguish between active and latent infection, and for this
reason the test is not accurate for the diagnosis of active TB
[12], which relies on the identiﬁcation of M. tuberculosis.
Use: Typically, interferon-gamma release assays can be
used in persons with an increased risk of new TB, such as
asymptomatic person after close contact with an active case
of pulmonary/respiratory TB, and in patients with an
increased risk of TB reactivation, such as patients infected
with human immunodeﬁciency virus, those with transplants,
lymphoma, leukaemia, head and neck cancer, chemother-
apy, or other therapeutic immunosuppression, and those
who will be treated with tumour necrosis factor-a inhibitors.
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